Cheryl Ann Pickett-Gies

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).”.

A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4604

N/A

0DataRank · unranked

2 citations

Elad Sharon, Cheryl Ann Pickett-Gies, Lisa Mac, Julia C. Friend, Erin B. Purcell +14 more

PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A children’s oncology group pediatric early-phase clinical Trial Network study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11527

N/A

0DataRank · unranked

11 citations

Katherine A. Janeway, Charles G. Minard, David Hall, Brian D. Crompton, Alexander J. Lazar +8 more